A Blockbuster Drug Gains Approval

Early yesterday evening, Biogen IDEC (Nasdaq: BIIB  ) and Elan (NYSE: ELN  ) announced that Tysabri had been approved by the FDA for the treatment of multiple sclerosis (MS). It's a great drug, but what a terrible name. Tysabri sounds more like the name of some obscure race in Star Trek or perhaps like some budget car produced in southeastern Europe. This drug was formerly called Antegren, so it's going to take time for some of us to get used to the new name.

Tysabri will compete with Biogen IDEC's own Avonex, Betaseron from Chiron (Nasdaq: CHIR  ) , Copaxone from Teva (Nasdaq: TEVA  ) , and Rebif from Serono (NYSE: SRA  ) . Though it is hardly a competition on equal footing. It's more like the Boston Red Sox playing the Bad News Bears. Just imagine Curt Schilling taking the hill against Tatum O'Neal.

Since head to head trials of Tysabri against any of these other products have not been conducted, no scientific claims of superiority can be made. That said, most people, including myself, think that Tysabri is automatically the new market leader. At the one-year mark in the phase 3 study AFFIRM, the rate of relapses was reduced by 66% compared to placebo. That result trounces all of the other products, which tend to reduce relapses by only one-third. This outcome represents a major advance in the treatment of MS.

Tysabri has long been regarded as a drug that will generate a whopping level of sales. That's a fairly reasonable assumption given the large size of this market. Now that the drug has been approved, I am fine-tuning my own numbers to come up with a peak sales estimate in the MS market. I will have that article up on the main page on December 7th. Be sure to check back then.

For additional articles on the biotech industry see:

Fool contributorCharly Traversdoes not own shares of any company mentioned in this article. Charly is also an analyst forMotley Fool Rule Breakers. If you'd like to see what David Gardner and his team of analysts have cooking, we invite you to take a risk-free trial with no obligation.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 503798, ~/Articles/ArticleHandler.aspx, 11/26/2014 4:46:29 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,827.75 12.81 0.07%
S&P 500 2,072.83 5.80 0.28%
NASD 4,787.32 29.07 0.61%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/26/2014 3:59 PM
BIIB $304.92 Down -0.48 -0.16%
Biogen Idec CAPS Rating: ****
ELN.DL2 $0.00 Down +0.00 +0.00%
Elan CAPS Rating: ***
TEVA $56.81 Up +0.23 +0.41%
Teva Pharmaceutica… CAPS Rating: *****

Advertisement